The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The future of myeloma: the potential role of MRD-driven therapy de-escalation strategies
In this video, Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly comments on the potential future use of measurable residual disease (MRD)-guided therapy de-escalation strategies in multiple myeloma (MM), highlighting that achieving sustained MRD negativity may allow for treatment de-escalation or even discontinuation in some patients. Although this approach is still in its early stages and more data is required to underpin its feasibility, Dr Zamagni believes it will revolutionize the treatment of myeloma. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Yeah, so for sure now MRD-negativity is a new endpoint for the trials and also for drug approval. So it means that more and more patients will be tested for MRD. So what is this meaning? I think that several trials have already shown that once you have achieved sustained MRD-negativity, it’s not making that much difference whether you are continuing treatment or not...
Yeah, so for sure now MRD-negativity is a new endpoint for the trials and also for drug approval. So it means that more and more patients will be tested for MRD. So what is this meaning? I think that several trials have already shown that once you have achieved sustained MRD-negativity, it’s not making that much difference whether you are continuing treatment or not. So probably this is a starting point –we have to push the highest number of patients into sustained MRD negativity and then we can think truly about either de-escalating one of the drugs, for example if it is a doublet, or to stop even the treatment. So of course we don’t have so many data about this, so we will have to start to generate, but I believe that this will be the way to go and it will be the future of myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Bristol Myers Squibb: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Menarini Stemline: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Oncopeptides: Honoraria, Membership on an entity’s Board of Directors or advisory committees.
